Cardiomax trial for Investigate readers
By Ian Wishart
The company behind a groundbreaking natural supplement for heart health is calling for volunteers to trial the product in New Zealand and diarise their comments on it.
Cardiomax, based on a patented Hawthorn extract, hit world scientific headlines five years ago literally: “Herbal extract extends life for heart failure patients”, reported Science Daily. It wasn’t some random claim, but the result of extensive studies by some of the world’s leading researchers on heart health.
“An herbal medicinal substance, Crataegus Extract WS®1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented at the American College of Cardiology’s 56th Annual Scientific Session.
“Crataegus Extract WS®1442 is an extract of leaves of the Crataegus tree, and is a natural antioxidant. The herb is currently approved for use in some European countries to treat early congestive heart failure, a condition in which the heart cannot pump enough blood to the body’s other organs.
“A total of 2,681 patients with markedly impaired left ventricular function–indicating advanced congestive heart failure– were randomized to WS®1442 or placebo for a duration of two years. All patients were already receiving pharmacological therapy with ACE-inhibitors (83 %), betablockers (64 %), glycosides (57 %), spironolactone (39 %) and diuretics (85 %).
“Dr. Christian J. F. Holubarsch and his team saw a 20 percent reduction in cardiac related deaths among patients on WS®1442, extending patients’ lives by four months during the first 18 months of the study. The safety of the compound was confirmed by a lower number of adverse events among the study group than those on placebo.
“ ‘WS 1442 is safe in patients with more severe congestive heart failure and left ventricular ejection fraction lower than 35 percent,’ said Dr. Holubarsch of Median Kliniken Hospitals in Bad Krozingen, Germany, and lead study author. ‘It postpones death of cardiac cause after 18 months and sudden cardiac death in an important subgroup of patients’.”
You would think after endorsements like this that New Zealand cardiologists would be prescribing Cardiomax for their patients, but the product can’t get traction. The highly respected international medical panel known as the Cochrane Collaboration has told world health agencies, “there is a significant benefit in symptom control and physiologic outcomes from hawthorn extract as an adjunctive treatment for chronic heart failure.”
Hence the New Zealand trial. Investigate magazine and the makers of Cardiomax are seeking 20 volunteers to register a “like” on our Facebook page, facebook.com/pages/Investigate-Magazine, then send us a message confirming you’d like to take part in the trial and providing a contact email address.
We’re looking for two different groups:
- Those who are prone to fatigue and who need more get up and go. These may fall into two sub groups:
- A general decline of the cardiovascular system
- recovering from heart problems
2. Those who want to protect their heart; that is de-stress it.
The key point to remember are that this is not a “clinical” trial – Cardiomax has already been extensively clinically-trialled worldwide and passed with flying colours. Instead, what we’re looking for is anecdotal reports of your usage and how your health changes as a result over time.
Secondly, Cardiomax has been clinically approved as safe to use alongside existing pharmaceutical heart drugs, so can be taken by anyone even if already in medical care.
Thirdly, Cardiomax is based on a natural product, not synthetic medication.
Fourthly, Cardiomax is recommended by Australian cardiologists to their patients and by heart specialists around the world.
To volunteer for the product trial, visit Investigate Magazine’s Facebook page, register a like and then message us with your contact details.